Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.
Also called NCT02280486
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 388 participants
- Sponsor
- Registry
-
NCT02280486
-
- Other papers using this trial's data
- Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02280486. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
- Acronym
- SPECIFY
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Collaborator
- The First Affiliated Hospital with Nanjing Medical University
- Collaborator
- Zhongda Hospital
- Collaborator
- Nanjing PLA General Hospital
- Collaborator
- Changzhou No.2 People's Hospital
- Collaborator
- The First Affiliated Hospital of Soochow University
- Collaborator
- Wuxi People's Hospital
- Collaborator
- The First Affiliated Hospital of Anhui Medical University
- Collaborator
- Huai'an First People's Hospital
Record details
- Record id
cardio:ct-nct02280486- Content hash
a5dab4d4650efba12642d054764b41463fe8ac57ec18c9931167d6fe11d0115d